NO306257B1 - 11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav - Google Patents

11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav

Info

Publication number: NO306257B1
Authority: NO; Norway
Prior art keywords: ostra; pharmaceutical composition; substituted phenyl; diene derivatives; diene
Prior art date: 1995-08-17

Application number

NO963427A

Other languages

English (en)

Norwegian (no)

Other versions

NO963427L (no

NO963427D0 (no

Inventor

Ronald Gebhard

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-17

Filing date

1996-08-16

Publication date

1999-10-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO306257(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-08-16 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

1996-08-16 Publication of NO963427D0 publication Critical patent/NO963427D0/no

1997-02-18 Publication of NO963427L publication Critical patent/NO963427L/no

1999-10-11 Publication of NO306257B1 publication Critical patent/NO306257B1/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO963427A 1995-08-17 1996-08-16 11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav NO306257B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP95202229		1995-08-17

Publications (3)

Publication Number	Publication Date
NO963427D0 NO963427D0 (no)	1996-08-16
NO963427L NO963427L (no)	1997-02-18
NO306257B1 true NO306257B1 (no)	1999-10-11

Family

ID=8220570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO963427A NO306257B1 (no)	1995-08-17	1996-08-16	11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav

Country Status (25)

Country	Link
US (1)	US6011025A (cs)
EP (1)	EP0763541B1 (cs)
JP (1)	JP3977462B2 (cs)
KR (1)	KR100445376B1 (cs)
CN (1)	CN1129602C (cs)
AR (1)	AR003982A1 (cs)
AT (1)	ATE182596T1 (cs)
AU (1)	AU711369B2 (cs)
BR (1)	BR9603429A (cs)
CA (1)	CA2182771C (cs)
CZ (1)	CZ287740B6 (cs)
DE (1)	DE69603425T2 (cs)
DK (1)	DK0763541T3 (cs)
ES (1)	ES2137625T3 (cs)
GR (1)	GR3031116T3 (cs)
HU (1)	HU229023B1 (cs)
IL (1)	IL118974A (cs)
NO (1)	NO306257B1 (cs)
NZ (1)	NZ299181A (cs)
PL (1)	PL183468B1 (cs)
RU (1)	RU2135514C1 (cs)
SG (1)	SG52834A1 (cs)
TR (1)	TR199600664A2 (cs)
TW (1)	TW464654B (cs)
ZA (1)	ZA966555B (cs)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0903146A1 (en) *	1997-09-23	1999-03-24	Applied Research Systems ARS Holdings N.V.	21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
ATE332696T1 (de)	1997-10-06	2006-08-15	Univ Leland Stanford Junior	Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
EP1726307A3 (en) *	1997-10-06	2007-04-04	The Board Of Trustees Of The Leland Stanford Junior University	Methods for treating psychosis associated with glucocorticoid related dysfunction
KR20010043630A (ko)	1998-05-15	2001-05-25	더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티	치매의 치료를 위한 글루코코티코이드 수용체 길항제
EP1212345B1 (en) *	1999-04-06	2003-08-06	Akzo Nobel N.V.	Orally active 7-alpha-alkyl androgens
MXPA03007261A (es) *	2001-02-14	2006-03-09	Abbott Lab	Moduladores del receptor de glucocorticoides.
EP1285927A3 (de)	2001-08-16	2005-06-29	Schering Aktiengesellschaft	Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
KR20050038580A (ko) *	2001-10-26	2005-04-27	악조 노벨 엔.브이.	주요 우울 장애의 치료에 사용되는(11β,17β)-11-(1,3-벤조디옥솔-5-일)-17-히드록시-17-(1-프로피닐)-에스트라-4,9-디엔-3-온의 용도
WO2003043640A2 (en) *	2001-11-23	2003-05-30	Akzo Nobel N.V.	Treatment of major depressive disorder using glucocorticoid receptor antagonists
JP2006508951A (ja) *	2002-11-05	2006-03-16	コーセプトセラピューティクス，インコーポレイテッド	片頭痛を処置するための方法
EP1599208A4 (en) *	2003-02-04	2007-09-12	Corcept Therapeutics Inc	ANTIGLUCOCORTICOIDES FOR THE TREATMENT OF POSTPARTAL PSYCHOSIS
TW200820977A (en)	2006-08-08	2008-05-16	Organon Nv	Use of glucocorticoid receptor antagonists for treatment of infectious conditions
EP2671086B1 (en) *	2011-02-03	2018-04-25	Pop Test Oncology LLC	System and method for diagnosis and treatment
US20120245552A1 (en) *	2011-03-23	2012-09-27	Pop Test Cortisol Llc	Combination Therapy
WO2012135274A1 (en)	2011-03-31	2012-10-04	Pop Test Cortisol Llc	Prevention of infection
US20120263660A1 (en) *	2011-04-18	2012-10-18	Pop Test Cortisol Llc	Hair Loss Treatment
US8986677B2 (en)	2012-07-30	2015-03-24	Pop Test Cortisol Llc	Therapeutic compositions and methods
EP3151906B1 (en)	2014-06-03	2019-12-11	Pop Test Abuse Deterrent Technology LLC	Drug device configured for wireless communication
CN107530435A (zh) *	2015-03-02	2018-01-02	科赛普特治疗学股份有限公司	使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
MX385372B (es)	2015-03-23	2025-03-18	Evestra Inc	Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos
WO2016160969A1 (en)	2015-03-30	2016-10-06	Corcept Therapeutics, Inc.	Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
EP3400233B1 (en) *	2015-08-03	2025-10-22	Pop Test Oncology LLC	Pharmaceutical compositions and methods
US9598459B2 (en) *	2015-08-03	2017-03-21	Pop Test Oncology Llc	Pharmaceutical compositions and methods
ES2865334T3 (es)	2015-08-13	2021-10-15	Corcept Therapeutics Inc	Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH
CN108699102A (zh) *	2015-12-23	2018-10-23	欧瑞克制药公司	糖皮质激素受体抑制剂
US11208432B2 (en)	2015-12-23	2021-12-28	Oric Pharmaceuticals, Inc.	Inhibitors of glucocorticoid receptor
WO2017112904A1 (en)	2015-12-23	2017-06-29	Oric Pharmaceuticals, Inc.	Inhibitors of glucocorticoid receptor
CA3011728A1 (en)	2016-01-19	2017-07-27	Corcept Therapeutics, Inc.	Differential diagnosis of ectopic cushing's syndrome
MX385658B (es) *	2016-10-07	2025-03-18	Oric Pharmaceuticals Inc	Inhibidores del receptor de glucocorticoides.
AU2018289307B2 (en)	2017-06-20	2024-02-01	Corcept Therapeutics, Inc.	Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
AU2020239920A1 (en)	2019-03-18	2021-11-04	Arnold L. Newman	Method of improving insulin sensitivity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA8231B (en) *	1981-01-09	1982-11-24	Roussel Uclaf	New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) *	1982-03-01	1986-02-14	Roussel Uclaf	Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
US4780461A (en) *	1983-06-15	1988-10-25	Schering Aktiengesellschaft	13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3625315A1 (de) *	1986-07-25	1988-01-28	Schering Ag	11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
IE60780B1 (en) *	1987-01-23	1994-08-10	Akzo Nv	New 11-aryl steroid derivatives
DE3708942A1 (de) *	1987-03-18	1988-09-29	Schering Ag	19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3717169A1 (de) *	1987-05-19	1988-12-01	Schering Ag	19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3723788A1 (de) *	1987-07-16	1989-01-26	Schering Ag	11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3822770A1 (de) *	1988-07-01	1990-01-04	Schering Ag	13-alkyl-11ss-phenylgonane
ATE172469T1 (de) *	1989-08-04	1998-11-15	Schering Ag	11 beta-aryl-gona-4,9-dien-3-one
JP3828926B2 (ja) *	1993-08-04	2006-10-04	アクゾ・ノベル・エヌ・ベー	不安症の治療用抗グルココルチコイドステロイド
DE69500542T2 (de) *	1994-05-19	1998-01-02	Akzo Nobel Nv	11,21-Bisphenyl-19-nor-pregnan Derivate

1996
- 1996-07-29 IL IL11897496A patent/IL118974A/en not_active IP Right Cessation
- 1996-08-01 ZA ZA9606555A patent/ZA966555B/xx unknown
- 1996-08-06 CA CA002182771A patent/CA2182771C/en not_active Expired - Fee Related
- 1996-08-12 JP JP21282496A patent/JP3977462B2/ja not_active Expired - Fee Related
- 1996-08-13 DK DK96202273T patent/DK0763541T3/da active
- 1996-08-13 AT AT96202273T patent/ATE182596T1/de active
- 1996-08-13 CZ CZ19962386A patent/CZ287740B6/cs not_active IP Right Cessation
- 1996-08-13 EP EP96202273A patent/EP0763541B1/en not_active Expired - Lifetime
- 1996-08-13 ES ES96202273T patent/ES2137625T3/es not_active Expired - Lifetime
- 1996-08-13 DE DE69603425T patent/DE69603425T2/de not_active Expired - Lifetime
- 1996-08-14 BR BR9603429A patent/BR9603429A/pt not_active IP Right Cessation
- 1996-08-14 KR KR1019960033671A patent/KR100445376B1/ko not_active Expired - Fee Related
- 1996-08-14 SG SG1996010458A patent/SG52834A1/en unknown
- 1996-08-15 TR TR96/00664A patent/TR199600664A2/xx unknown
- 1996-08-15 NZ NZ299181A patent/NZ299181A/en not_active IP Right Cessation
- 1996-08-16 HU HU9602269A patent/HU229023B1/hu not_active IP Right Cessation
- 1996-08-16 NO NO963427A patent/NO306257B1/no not_active IP Right Cessation
- 1996-08-16 AU AU62119/96A patent/AU711369B2/en not_active Ceased
- 1996-08-16 RU RU96115774/04A patent/RU2135514C1/ru not_active IP Right Cessation
- 1996-08-16 AR ARP960104036A patent/AR003982A1/es unknown
- 1996-08-16 PL PL96315733A patent/PL183468B1/pl not_active IP Right Cessation
- 1996-08-16 CN CN96111830A patent/CN1129602C/zh not_active Expired - Fee Related
- 1996-08-22 TW TW085110266A patent/TW464654B/zh not_active IP Right Cessation
1997
- 1997-09-22 US US08/935,360 patent/US6011025A/en not_active Expired - Lifetime
1999
- 1999-08-31 GR GR990402198T patent/GR3031116T3/el unknown

Also Published As

Publication number	Publication date
PL315733A1 (en)	1997-03-03
MX9603476A (es)	1997-07-31
CN1129602C (zh)	2003-12-03
KR970010784A (ko)	1997-03-27
NO963427L (no)	1997-02-18
US6011025A (en)	2000-01-04
ZA966555B (en)	1997-02-19
CA2182771C (en)	2007-04-24
DK0763541T3 (da)	2000-02-28
AU711369B2 (en)	1999-10-14
CZ287740B6 (en)	2001-01-17
HU229023B1 (en)	2013-07-29
IL118974A0 (en)	1996-10-31
HUP9602269A3 (en)	1997-12-29
EP0763541A1 (en)	1997-03-19
AU6211996A (en)	1997-02-20
DE69603425T2 (de)	2000-01-20
JP3977462B2 (ja)	2007-09-19
KR100445376B1 (ko)	2004-11-08
SG52834A1 (en)	1998-09-28
CA2182771A1 (en)	1997-02-18
BR9603429A (pt)	1998-05-12
TR199600664A2 (tr)	1997-03-21
GR3031116T3 (en)	1999-12-31
NO963427D0 (no)	1996-08-16
IL118974A (en)	2001-09-13
ES2137625T3 (es)	1999-12-16
TW464654B (en)	2001-11-21
CZ238696A3 (en)	1997-05-14
HU9602269D0 (en)	1996-10-28
HUP9602269A2 (en)	1997-04-28
NZ299181A (en)	1997-09-22
CN1147520A (zh)	1997-04-16
DE69603425D1 (de)	1999-09-02
HK1002010A1 (en)	1998-07-24
ATE182596T1 (de)	1999-08-15
EP0763541B1 (en)	1999-07-28
JPH09104696A (ja)	1997-04-22
PL183468B1 (pl)	2002-06-28
RU2135514C1 (ru)	1999-08-27
AR003982A1 (es)	1998-09-30

Legal Events

Date	Code	Title	Description
2014-03-24	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO306257B1 (no)	1999-10-11	11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav
NO973612D0 (no)	1997-08-05	Nytt farmasöytisk preparat
NO307707B1 (no)	2000-05-15	Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
NO306401B1 (no)	1999-11-01	Oksazolidindionderivater, farmasöytisk preparat inneholdende slike derivater, og deres anvendelse
DE69513671D1 (de)	2000-01-05	Arzneimittel
DE69737936D1 (de)	2007-08-30	Arzneimittel
NO20021379D0 (no)	2002-03-20	Benzodiazepin-derivater, fremstilling og anvendelse derav
NO980720D0 (no)	1998-02-20	Pyridazin-3-on-derivater, deres anvendelse og mellomprodukter for deres fremstilling
NO996372L (no)	2000-02-23	Fast farmasøytisk preparat inneholdende benzofuanderivater
NO308533B1 (no)	2000-09-25	Heteroarylaminer, anvendelse derav og farmasøytisk preparat
NO307092B1 (no)	2000-02-07	Sordaridin-derivater, anvendelse derav og farmasoeytisk blanding
NO20011157D0 (no)	2001-03-07	Benzenderivater og farmasøytisk anvendelse derav
NO308394B1 (no)	2000-09-11	Oralt preparat
NO20005399D0 (no)	2000-10-26	Farmasøytisk preparat
DK1025100T3 (da)	2002-05-06	3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
NO973610D0 (no)	1997-08-05	Nytt farmasöytisk preparat
LV11727A (lv)	1997-04-20	Farmaceitiska kompozicija
EE9800209A (et)	1998-12-15	Antiglükokortikoidne ravimaine
ID18698A (id)	1998-04-30	Komposisi farmasi
FI973280L (fi)	1997-08-08	Farmaseuttinen koostumus
NO973611D0 (no)	1997-08-05	Nytt farmasöytisk preparat
NO950950D0 (no)	1995-03-13	Farmasöytisk preparat
NO20000066D0 (no)	2000-01-06	6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
FI961364L (fi)	1997-09-26	Lääkeainekoostumus
NO982549D0 (no)	1998-06-04	5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav